Advertisement
C.R. Bard
Subscribe to C.R. Bard

The Lead

Panel Provides Unanimous Favorable Recommendation to FDA for Bard's Drug Coated Balloon

June 12, 2014 8:28 pm | by The Associated Press | News | Comments

C. R. Bard, Inc. today announced that the U.S. Food and Drug Administration’s (FDA) Circulatory System Devices Advisory Panel provided a unanimous favorable recommendation to FDA for use of the Lutonix Drug Coated Balloon PTA Catheter (DCB)...

Bard bellwether mesh trial delayed until 2014

December 3, 2013 2:53 pm | by Mass Device | News | Comments

Patients in another bellwether trial against C.R. Bard will have to wait another month to air...

Boston Scientific Completes Acquisition of Bard Electrophysiology

November 1, 2013 12:07 pm | by PR Newswire | News | Comments

Boston Scientific Corporation closed on its previously announced agreement to acquire Bard EP,...

Gore begins $857M Bard payback with $36M royalty payment

October 31, 2013 1:58 pm | by Mass Device | News | Comments

W.L. Gore & Associates began paying out the $857.4 million it owes C.R. Bard for infringing...

View Sample

FREE Email Newsletter

C.R. Bard shifts jobs to upstate N.Y.

October 30, 2013 12:01 pm | by Mass Device | News | Comments

C.R. Bard began adding jobs in its Queensbury, N.Y., facility, adding 30-40 positions after 2 rounds of layoffs last year. The Murray Hill, N.J.-based firm shifted product lines it acquired to the upstate New York plant, vice president & treasurer...

Bard seeks to recoup legal costs in dismissed Avaulta bellwether

October 16, 2013 9:57 am | by Mass Device | News | Comments

C.R. Bard wants to recoup its legal costs from a bellwether lawsuit over its Avaulta pelvic mesh that was dismissed last month, asking a federal judge to order the plaintiffs to pony up some $14,000. Judge Joseph Goodwin of the U.S. District Court...

Rochester Medical To Hold Special Meeting Of Shareholders November 13, 2013 To Approve Definitive Agreement To Be Acquired By C.R. Bard

October 10, 2013 6:14 pm | by PR Newswire | News | Comments

Rochester Medical Corporation has established a record date and a special meeting date for the Company's shareholders to consider and vote on the proposal to adopt the previously announced agreement to be acquired by a subsidiary of C.R. Bard...

Advertisement

CryoLife to cash in on Bard buyout of Medafor

October 8, 2013 11:32 am | by Mass Device | News | Comments

CryoLife Inc. said it's in line for a $15.1 million payout from the C.R. Bard acquisition of Minnesota-based Medafor for up to $280 million. CryoLife said it owns nearly 2.4 million shares of Medafor stock, which cost it about $2.6 million...

Bard puts a ribbon on $280M Medafor acquisition

October 4, 2013 1:49 pm | by Mass Device | News | Comments

C.R. Bard tied a bow on its previously announced acquisition of Minnesota-based Medafor in a deal worth up to $280 million. Officially consummated on October 1, the deal provided $200 million up-front and another possible $80 million for Medafor and its line of anti-bleeding agents.

VasoNova, Bard settle trade secret theft suit

October 4, 2013 11:15 am | by Mass Device | News | Comments

A C.R. Bard subsidiary settled a lawsuit filed against it by VasoNova alleging that Bard and an ex-technology chief stole trade secrets to set up a new company. VasoNova makes a system that uses Doppler ultrasound and intravascular ECG to help cardiologists place catheters in the heart.

Rochester Medical skyrockets on $262M Bard acquisition news

September 4, 2013 1:29 pm | by Mass Device | News | Comments

Both C.R. Bard and Rochester Medical got some stock market love today after the companies signed a definitive merger agreement, but Rochester was the clear Wall Street darling with a more than 40% bump in shares by early afternoon trading.    

Bard Announces Agreement to Acquire Medafor, Inc.

August 19, 2013 8:00 am | by Business Wire | News | Comments

C. R. Bard, Inc. has announced that it has entered into a definitive agreement to acquire privately-held Medafor, Inc., a leading developer and supplier of plant based hemostatic agents for the purchase price of $200 million paid at closing, expected to occur later this year, and future contingent payments up to an additional $80 million based on specific revenue-based milestones through June 30, 2015.

Advertisement

Bard Avaulta mesh case ends in mistrial

July 10, 2013 3:44 pm | by Mass Device | News | Comments

The trial of a personal injury lawsuit filed against C.R. Bard ended in mistrial today after a federal judge granted Bard's motion to dismiss, according to court documents. Judge Joseph Goodwin declared a mistrial at 2:15 p.m. today, according to the documents, during the 2nd day of the trial.

Boston Scientific To Acquire C.R. Bard Electrophysiology Business

June 28, 2013 8:30 am | by PR Newswire | News | Comments

In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific has entered into a definitive agreement to acquire Bard EP, the electrophysiology business of C.R. Bard, for $275 million in cash.

C.R. Bard Loses Patent Round, $25M Hernia Insurance Decision

April 1, 2013 9:54 pm | by Mass Device | News | Comments

C.R. Bard revealed a 1-2 punch today when it reported another loss in its patent infringement war with W.L. Gore and an adverse insurance decision that could cost it $25 million. The medical device company said in regulatory filings that the U.S. Patent & Trademark Office issued an initial finding in its reexamination of a Bard patent for a "Prosthetic vascular graft," known as the '135 patent.

Bard to Present at Barclays Global Healthcare Conference

March 6, 2013 10:30 am | by The Associated Press | News | Comments

MURRAY HILL, N.J.--(BUSINESS WIRE)--Mar 6, 2013--C. R. Bard, Inc. (NYSE: BCR) today announced that it will present at the Barclays Global Healthcare Conference in Miami, Florida on March 13, 2013. Timothy M. Ring, chairman and chief executive officer, will discuss the Company in a presentation...

Bard to Present at Raymond James Institutional Investor Conference

February 25, 2013 10:30 am | by The Associated Press | News | Comments

MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb 25, 2013--C. R. Bard, Inc. (NYSE: BCR) today announced that it will present at the Raymond James Institutional Investor Conference in Orlando, Florida on March 4, 2013. Christopher S. Holland, senior vice president and chief financial officer, will discuss...

Advertisement

Bard to Present at Citi 2013 Global Healthcare Conference

February 14, 2013 4:21 pm | by The Associated Press | News | Comments

MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb 14, 2013--C. R. Bard, Inc. (NYSE: BCR) today announced that it will present at the Citi 2013 Global Healthcare Conference in New York City on February 27, 2013. Timothy M. Ring, chairman and chief executive officer, will discuss the Company in a presentation...

M&A: The top 15 acquirers among medical device companies

August 6, 2012 3:37 pm | by Mass Device | News | Comments

A look at the most acquisitive medical device companies, culled from MassDevice.com's Big 100 database of more than 1,300 medical device industry transactions. More than $50 billion was spent on acquisitions by Big 100 medical device companies from the beginning of 2011 through the 1st half of 2012.

Bard Acquires Lutonix, Inc.

December 22, 2011 5:45 am | News | Comments

MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. today announced that it has acquired Lutonix, Inc. for a purchase price of approximately $225 million paid at closing, with an additional $100 million to be paid upon PMA approval of Lutonix's drug-coated percutaneous transluminal angioplasty (PTA) balloon.

C.R. Bard closes $200 M acquisition of SenoRx

July 6, 2010 8:45 am | by The Associated Press | News | Comments

C.R. Bard has closed on its acquisition of SenoRx, the medical device maker said Tuesday.SenoRx makes devices used in detecting and treating breast cancer and in May, Bard announced it would buy the company for about $200 million.SenoRx's products include the EnCor breast biopsy system, Gel...

Products for Tomorrow

April 1, 2005 4:54 am | Foster-Miller Inc. | Product Releases | Comments

Nova Biomedical needed high-volume production capability to produce disposable strips for its glucose monitoring system, which is currently distributed as the Logic Blood Glucose Monitor by BD. An outside engineering firm designed and built manufacturing equipment to fit its requirements.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading